RT info:eu-repo/semantics/article T1 Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors A1 González Martínez, Alicia A1 Guerrero Peral, Angel Luis A1 Arias Rivas, Susana A1 Silva, Lorenzo A1 Sierra, Álvaro A1 Gago Veiga, Ana Beatriz A1 García Azorín, David K1 Migraine K1 Amitriptyline K1 COVID-19 K1 Tension-type headache K1 Long-haulers K1 32 Ciencias Médicas AB Background Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We aimed to assess the efectiveness, side efects and predictors of amitriptyline (AMT) response in a real-world study setting.Methods We performed an observational multicentric study with a retrospective cohort. All consecutive patients with con frmed COVID-19 infection who received AMT for post-COVID headache from March 2020 to May 2021 were included. Response was evaluated by the reduction in the number of headache days per month (HDM) between weeks 8 and 12, compared with the baseline. We explored which variables were associated with a higher probability of response to AMT.Results Forty-eight patients were eligible for the study, 40/48 (83.3%) females, aged 46.85 (SD: 13.59) years. Patients had history of migraine 15/48 (31.3%) or TTH 5/48 (10.4%). The mean reduction of HDM was 9.6 (SD: 10.9; 95% CI 6.5, 12.7) days. Only 2/48 (5%) of patients discontinued AMT due to poor tolerability. History of TTH (10.9, 95% CI 1.3, 20.6) and nausea (−8.5, 95% CI −14.6, −2.5) were associated with AMT response.Conclusions This study provides real-world evidence of the potential beneft of AMT in patients with post-COVID-19 headache, especially in patients with history of TTH and without concomitant nausea. PB Springer SN 0340-5354 YR 2022 FD 2022 LK https://uvadoc.uva.es/handle/10324/54400 UL https://uvadoc.uva.es/handle/10324/54400 LA eng NO Journal of Neurology, 2022. NO Producción Científica DS UVaDOC RD 05-dic-2024